Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2012 May 15.
Published in final edited form as:
PMCID: PMC3096848

Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10−/− mice


Recently we reported that the ATP-binding cassette transporter Abcc10, also known as multidrug resistance protein 7 (Mrp7), is able to confer resistance to a variety of anticancer agents including taxanes. However, the in vivo functions of the pump have not been determined to any extent. Here we generated and analyzed Abcc10−/− mice in order to investigate the ability of Abcc10 to function as an endogenous resistance factor. Mouse embryo fibroblasts derived from Abcc10 −/− mice were hypersensitive to docetaxel, paclitaxel, vincristine and Ara-C and exhibited increased cellular drug accumulation, relative to wild type controls. Abcc10 null mice treated with paclitaxel exhibited increased lethality associated with neutropenia and marked bone marrow toxicity. Toxicity in spleen and thymus was also evident. These findings indicate that Abcc10 is dispensable for health and viability, and that it is an endogenous resistance factor for taxanes, other natural product agents and nucleoside analogs. This is the first demonstration that an ATP-binding cassette transporter other than P-glycoprotein can affect in vivo tissue sensitivity towards taxanes.

Keywords: Drug transport, drug resistance, Mrp7, Abcc10, taxanes, paclitaxel


Paclitaxel and its semi-synthetic analogue, docetaxel, have established roles in the treatment of common cancers such as breast, lung and prostate, as well as other less common tumors such as ovary and head and neck (1). Taxanes exert cytotoxicity by stabilizing microtubules and inducing cell cycle arrest. Because of the clinical utility of taxanes, cellular factors that affect sensitivity have been extensively investigated. Several mechanisms of resistance have been identified using cellular models of acquired taxane resistance, including increased expression of the P-glycoprotein drug efflux pump, acquired mutations in tubulin, increased expression of specific tubulin isoforms and alterations in signaling pathways involved in tubulin function (2, 3). Correlative clinical studies have largely highlighted the importance of two of these mechanisms - increased expression of P-glycoprotein and of the class III beta tubulin (48).

Recently we determined that ABCC10 (MRP7), a member of the MRP family of drug efflux pumps, is a novel cellular resistance factor for taxanes (913). Analysis of the drug resistance capabilities of ABCC10 in stably transfected HEK293 cells revealed that it is unique among MRPs in that taxanes are a prominent feature of its resistance profile (12). In addition, ABCC10 is able to confer resistance to another class of microtubule active agents - vinca alkaloids - and to certain nucleoside analogs (13). Ectopic expression of the pump in highly drug sensitive Mrp1−/−/Mdr1a/b−/− (Abcc1, Abcb1a/Abcb1b) fibroblasts confirmed the facility of ABCC10 for conferring resistance to taxanes and vincristine, and in addition uncovered its activity towards a range of other natural product agents including daunorubicin, etoposide and SN-38 (13). Insights into the substrate selectivity of ABCC10 have been afforded by in vitro transport studies. In addition to largely hydrophobic molecules such as natural product anticancer drugs, ABCC10 is able to transport amphipathic anions, as is the case for other MRPs (10). Among a number of organic anions previously identified as transport substrates of other MRPs, the selectivity of ABCC10 appears to be restricted to glucuronides such as E217βG, with additional modest activity towards the glutathione conjugate LTC4 (14).

While these studies provided insights into the in vitro properties of ABCC10 as assessed in transfected cell lines and transport assays and suggest that ABCC10 could play a role in sensitivity towards taxanes, little is currently known about the in vivo functions of the pump. To gain insights into the physiological and pharmacological functions of ABCC10, and in particular to determine its contribution to inherent sensitivity towards taxanes, an Abcc10−/− mouse was generated and analyzed. Here, it is shown that Abcc10−/− mice are sensitized to paclitaxel and that cell lines derived from this mouse model are hypersensitive to this agent, other natural product agents and Ara-C. We conclude that Abcc10 is dispensable for health and viability and that it contributes to the intrinsic resistance of cells and tissues towards several commonly employed chemotherapeutic agents, including taxanes.

Material and Methods

Targeted disruption of the Abcc10 gene and generation of Abcc10−/− mice

A mouse strain 129-derived lambda phage genomic library was probed with a 389-bp fragment containing the 5’ end of the Abcc10 coding sequence, and a ~12-kb Abcc10 clone was isolated. Nucleotide sequence analysis (ABI 377 DNA sequencer; Applied Biosystems, Foster City, CA) indicated that the clone encompassed exons 6–16 (amino acids 204–410) of the Abcc10 gene, corresponding to nucleotides 612-231 of the coding sequence. The left and right arms of a targeting vector were excised and inserted, respectively, into the 5’ and 3’ cloning sites of the pgk-neo cassette of the PNT plasmid (15). The resulting vector was designed to delete exons 6 – 8, encoding amino acids 204–332 (nucleotides 612–996). As a result, the Walker B motif required for nucleotide binding is deleted and a frame-shift is introduced in the coding sequence.

The nucleotide sequence of the cloned arms was confirmed, and the ~5.4 kb targeting vector was linearized with NotI. The vector was electroporated into strain 129-derived R1 embryonic stem cells, and individual colonies isolated after positive/negative selection with G418 and gancyclovir (15). EcoR1-digested genomic DNA was prepared and analyzed for proper right arm recombination by Southern blot analysis using a 3’ probe. A PCR strategy was used to identify correct left arm recombinants. The primers were 5’ CCT TTT GCC CCA CAT CTC AACC 3’ (Abcc10 sequence), and 5’ CGAGGGCCCCTGCAGGTC 3’ (vector sequence). The absence of randomly integrated vector sequences was confirmed by Southern blot analysis using a neomycin probe. Prior to injection into blastocysts, left arm recombination was confirmed by Southern blot analysis.

Two correctly targeted ES clones were injected into C57BL/6J blastocysts, and the blastocysts were implanted in pseudopregnant females. Male chimeric progeny were crossed with female C57BL/6J (in-house–bred) mice. Germ-line transmission of the targeted allele was confirmed by Southern blot analysis, as described above for the right arm, and for the left arm by PCR using: 5’-GTCCAACCTTTTGCCCCACATCT-3’ and 5’-AATTGACCTGCAGGGGCCCTCG-3’, which generates a ~3.5 Kb band. Subsequent genotyping was accomplished by PCR analysis of tail DNA using a single tube 3-primer reaction with: 5’- CCTGCCTGCTGGAGACCAG-3’, 5’-CCCAGGTGTCAAGGCAACTG-3’, and 5’-AATTGACCTGCAGGGGCCCTC-3’. The first two primers generate a 400-bp wild-type product, and the latter pair generate a 200-bp product from the targeted allele. As experiments proceeded using mixed strain mouse (C57BL/6J × 129) knock out mice, the Abcc10 null allele was backcrossed for eight generations onto the C57BL/6J background.

Antibody preparation and immunoblot analysis

A cDNA fragment encoding amino acids 1443 – 1491 of Abcc10 was inserted into pGEX-T (Amersham Biosciences, Piscataway, NJ) and the resulting glutathione S-transferase fusion protein was purified using glutathione beads according to the manufacturer’s recommendations. Rabbits were immunized with the purified recombinant protein and the specificity of the resulting antiserum was confirmed on membranes prepared from ABCC10 baculovirus-infected cells. Abcc10 was detected in kidney cells and spleen tissue using polyclonal antibody (1:5000) and an alkaline phosphatase-conjugated secondary antibody (1:30,000). ABCC10 antibody (P18, Santa Cruz Biotechnology, Santa Cruz, CA) (1:200) and an alkaline phosphatase-conjugated secondary antibody (1:2000) was used for the mouse embryo fibroblast immunoblot. Total cellular lysates prepared from cultured cells and spleen membrane fractions were subjected to SDS-polyacrylamide gel electrophoresis and proteins were electrotransferred to nitrocellulose filters. All blots were incubated with antibodies using the Millipore Snap ID system. β-Actin antibody (Cell Signaling Technology, Danvers, MA) was used at a concentration of 1:5000.

Cell line preparation and cellular assays

To prepare mouse embryo fibroblasts mice (C57BL/6J × 129 and C57BL/6J) were set up in timed matings and at day 13–14 embryos were harvested. Embryos were minced, aspirated through a 1 mL syringe and incubated in 0.25% trypsin for 15 min in a 37°C incubator. The cells were spun down at 1000 rpm for 5 min and cell pellets were resuspended in 10% DMEM and plated into flasks. Confluent cells were transfected with a plasmid containing SV40 T antigen and a blasticidin resistance marker to select for immortal lines, as previously described (16). Genetic veracity of mouse embryo fibroblasts was verified by the Fox Chase Cancer Center Biomarker and Genotyping facility every two months, and upon defrosting new vials, using genotyping and/or qRT-PCR. Drug accumulation and cellular proliferation assays were performed as previously described (13, 17, 18). Vincristine, paclitaxel, and cytarabine (Ara-C) were purchased from Sigma Chemical Company (St. Louis, MO). [3H] paclitaxel was purchased from Moravek (Brea, CA).

Kidney cell line preparation

Kidneys isolated from wild-type and knock out mice were finely minced and placed into 10 mL of 0.02% collagenase and incubated for 2 h at 37°C. The cells were washed four times with serum free DMEM and then transferred to 1.6 mL of low calcium DMEM supplemented with 5% horse serum in a swine gelatin coated flask (19). The next day, the supernatant was removed and free floating cells were transferred to another flask. The resulting primary cultures were expanded and used for immunoblot analysis.

Sensitivity of mice to paclitaxel

For survival curves, wild-type and knock-out mice (C57/BL6x129) were administered various concentrations of paclitaxel as a single intraperitoneal injection and monitored for morbidity. For experiments in which white blood cell counts and body weight were analyzed, mice were administered a single 20 mg/kg intraperitoneal injection of paclitaxel and measurements of white blood cell counts and body weight were made daily for 6 days. Blood samples were obtained by orbital bleeding and white blood cells were isolated using Zap-Oglobin II (Beckman, Brea, CA) according to the manufacturer’s instructions. White blood cell counts were analyzed using a Coulter Z1 series particle counter (Beckman Coulter, Miami, FL). Paclitaxel (LC Laboratories, Woburn, MA) was dissolved in methanol at a concentration of 50 mg/mL and filter sterilized.

Animal handling, blood chemistries and hematology

Animals were maintained in the Fox Chase Cancer Center laboratory animal facility and housed in a temperature- and humidity-controlled environment under 12h light/dark cycles. Mice were fed a standard rodent diet (Lab Diet 5013, PMI Nutrition, Brentwood, MO) and had free access to water. The Fox Chase Institutional Animal Care and Use Committee approved the protocol. Peripheral blood was obtained by orbital bleeding. Blood chemistry and hematologic variables were determined at Antech Diagnostics (Farmingdale, NY).

Analysis of Abcc10 RNA expression in mouse tissues

Total RNA was isolated from various mouse tissues using the RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer’s suggestions. RNA was reverse-transcribed using the M-MLV reverse transcriptase and a mixture of anchored oligo-dT primers and random decamers. Aliquots of cDNA were used for qRT-PCR. The sequences of the primers were: GGGCAATTGGTCCGAACA, CTTGTTCCTTCTCAGCCCAGG and probe 6FAM-TGAGATCCTGCCGCTGGTACAAGCTG-BHQ1PCR master mix (Applied Biosystems, Foster City, CA) were used. Cycling conditions were 95°C, 15 min followed by 40 cycles (95°C, 15 sec; 60°C, 60 sec). A 5 points 4-fold dilutions standard curve was used to convert the Ct values into quantities. To compare transporter expression levels we normalized all mean quantity data to an independent gene Ppib (cyclophilin B). For these assays, two wild-type and two Abcc10 −/− samples were examined for spleen, and thymus. Further, two independent measurements were taken for each sample.

Histopathological analysis

Tissues were fixed in 10% phosphate-buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin/eosin.


Generation of Abcc10−/− mice

To examine the in vivo functions of Abcc10, an Abcc10-null mouse was generated by homologous recombination in ES cells. The vector targeted amino acids 204–410 of the protein, which harbor most of nucleotide binding domain 1 including the entire Walker B motif (Figure 1A). Southern blot (Figure 1B) and PCR analysis (not shown) confirmed correct recombination, and Abcc10−/− mice were derived. Analysis of Abcc10 transcript expression in mouse tissues revealed a wide distribution pattern, with highest levels in testes, bladder, kidney and ovary (Figure 1C). Based upon the high levels of Abcc10 transcript in kidney, this tissue was analyzed to evaluate loss of Abcc10 protein in Abcc10−/− mice. Abcc10 protein was readily detected in primary kidney cells lines isolated from wild type mice but was undetectable in kidney and spleen cells isolated from Abcc10 null mice, confirming the absence of Abcc10 protein in the knockout mice (Figure 1D). Loss of Abcc10 protein was also confirmed in spleen. Abcc10-null mice appeared normal with respect to appearance, behavior and fertility. Analysis of a panel of hematopoietic and blood chemistry parameters (Supplemental Table 1), and histopathological analysis of tissues, did not reveal significant differences between wild-type and Abcc10 null mice.

Fig. 1
Targeted disruption of the Abcc10 gene in mice

Abcc10−/− mouse embryo fibroblasts are hypersensitive to natural product agents and Ara-C

Mouse embryo fibroblast (MEF) cell lines were generated from Abcc10-null and wild type mice as a cellular model to study the protective function of Abcc10. Immunoblot analysis confirmed the presence of Abcc10 protein in wild-type MEFs but not in MEFs derived from Abcc10 knockout mice (Figure 2A). The cell lines were analyzed for sensitivity towards representative anticancer agents that we previously determined were components of the human ABCC10 drug resistance profile - paclitaxel, docetaxel, vincristine and Ara-C (12, 13). Abcc10−/− MEFs were hypersensitive to each of these agents (Figure 2B). The highest levels of hypersensitivity were observed towards docetaxel, for which Abcc10−/− MEFs were 22.2-fold more sensitive than wild-type MEFs (IC50 values of 0.59 ± 0.22 nM vs. 13.1 ± 3.8 nM, for Abcc10−/− and wild type MEFs, respectively; P = 0.031). For paclitaxel, vincristine and Ara-C, Abcc10−/− MEFs were 4.2, 2.3 and 3.9-fold more sensitive than wild-type MEFs (respective IC50 values of 55.1 ± 9.1, 29.2 ± 5.3 and 48.9 ± 10 nM for Abcc10−/− MEFs versus 229 ± 0.3, 66.0 ± 15, and 191 ± 27 nM for wild type MEFs; P = 0.004, 0.031 and 0.008, respectively).

Fig. 2
Drug resistance analysis of Abcc10−/− mouse embryo fibroblasts

The impact of genetic deficiency of Abcc10 was also evaluated in the context of MEFs isolated from Abcc10−/− mice that had been backcrossed to C57BL/6 (Figure 2C). A similar pattern of hypersensitivity was observed for this genetic background, with Abcc10−/− MEFs exhibiting 2.7, 1.2 and 3.9-fold increased sensitivity compared to wild-type MEFs (respective IC50 values of 229 ± 27, 258 ± 12 and 501 ± 130 µM for Abcc10−/− MEFs versus 83.9 ± 20, 219 ± 5.6 and 127 ± 22.3 nM for wild type MEFs; P = 0.0005, 0.016 and 0.016, respectively).

To confirm that the increased sensitivity of Abcc10-null MEFs was attributable to genetic deficiency of a drug efflux pump rather than secondary changes that might arise as a consequence of the Abcc10−/− lesion, the cellular kinetics of paclitaxel accumulation and efflux were analyzed (Figure 2D). As expected, accumulation of paclitaxel in Abcc10−/− MEFs was significantly greater than in wild-type cells, regardless of the background strain from which the MEFs were derived. Following a 30 min incubation in 0.1 µM [3H]paclitaxel, accumulation in Abcc10−/− MEFs was increased 44% and 63% respectively, in C57BL/6x129 and C57BL/6 Abcc10−/− fibroblasts, compared to their respective control cell lines (P=0.002 and .002, respectively). The accumulation deficit for paclitaxel was greater for genetic deficiency of Abcc10 in MEFs on the mixed genetic background compared to the C57BL/6 background, in close concordance with the higher levels of paclitaxel sensitization observed for Abcc10−/− MEFs on the mixed versus C57BL/6 background (Figures 2). Representative dose response curves for docetaxel, paclitaxel, vincristine and Ara-C using Abcc10−/− and wild-type MEFs derived from the C57BL/6J × 129 strain are shown in Figure 3(A–D). Increased sensitivity was observed for Abcc10−/− MEFs compared to wild-type MEFs for paclitaxel (Figure 3A), docetaxel (Figure 3B), vincristine (Figure 3C) and Ara-C (Figure 3D).

Fig. 3
Drug sensitivity curves for wild type and Abcc10−/− MEFs

Abcc10−/− mice are hypersensitive to paclitaxel

Having determined in the above in vitro experiments that genetic deficiency of Abcc10 confers cellular sensitivity to a range of agents including taxanes, the in vivo pharmacological functions of Abcc10 were investigated next by challenging Abcc10−/− and wild-type mice with paclitaxel. Sensitivity to paclitaxel was markedly increased in Abcc10−/− mice, as indicated by the striking separation of the dose-response curves (Figure 4A). The minimal toxic dose for Abcc10−/− mice was 32 mg/kg compared to 150 mg/kg for wild-type mice, or ~ 5-fold lower than that of wild-type mice. Only 33% of the Abcc10−/− mice survived at 160 mg/kg, whereas 10% of wild-type mice survived at this dose. At 250 mg/kg 100% of Abcc10−/− mice died, whereas 80% of wild-type mice survived.

Fig. 4
Toxicity of paclitaxel in wild type and Abcc10−/− mice

Body weight and white blood cell counts were analyzed in mice challenged with paclitaxel (Figure 4, B and C). Although the intention in this experiment was to select a dosage that was sublethal (20 mg/kg), significant morbidity was observed. Presumably, this was attributable to stress associated with daily orbital bleeds. Nevertheless, the increased sensitivity of Abcc10−/− mice towards paclitaxel was reflected in both body weight and white blood cell parameters. Wild-type mice lost no more than 10% of body weight and eventually recovered, whereas Abcc10−/− mice lost up to 20% of body weight. In wild-type mice, depression of white blood cell counts was not observed, whereas in Abcc10−/− mice striking reductions were apparent, with a 70% reduction observed at day 6.

Abcc10 protects bone marrow, spleen and thymus

Histopathologic analysis of wild-type and Abcc10−/− mice treated with paclitaxel revealed significant changes in hematopoietic and lymphoid tissues in Abcc10−/− mice, whereas the corresponding tissues in wild-type mice appeared little changed. Marked hypoplasia was seen in the bone marrow of Abcc10−/− mice, whereas wild-type mice exhibited minimal or no changes (Figure 5 A). Abcc10-null mice had smaller spleens in which the lymphoid follicles (white pulp) were diminished in number and size (Figure 5 B). In addition, erythroid and myeloid cell populations in the red pulp were decreased and replaced by histiocytes and stromal cells. In Abcc10−/− mice, the cortex of the thymus was decreased in size in association with lymphocyte apoptosis and/or depopulation (Figure 5 C). To gain further insight into these observations, qRT-PCR analysis of RNA isolated from spleen and thymus of Abcc10 −/− and wild-type mice was performed. Abcb1a, Abcb1b, Abcc1, Abcc3, Abcc4, and Abcc5 did not show statistically significant changes in gene expression levels as a result of Abcc10 knockdown. Further, the levels of Abcc2, Abcc6, and Abcc9 in these tissues were too low to draw conclusions. Overall, there were no strong compensatory changes based upon Abcc10 phenotype.

Fig. 5
Histopathologic analysis of bone marrow, spleen and thymus


In previous studies we determined that ectopic expression of ABCC10 confers resistance to taxanes, vinca alkaloids and a range of nucleoside analogs such as Ara-C (12, 13). Of these agents taxanes were of particular interest to us because of the paucity of efflux pumps, aside from P-glycoprotein, that are established cellular resistance factors for this class of clinically important agents. Indeed, the importance of P-glycoprotein in resistance to taxanes, and the potential for ABCC10 to function as a resistance factor for this class of agents, was highlighted by the extraordinary high levels of resistance ABCC10 is able to confer to paclitaxel and docetaxel (116 and 46-fold, respectively) when it was ectopically expressed in P-glycoprotein deficient fibroblasts (13). In view of the intriguing activities of ABCC10 in studies on transfected cells, the present study was undertaken to investigate the potential for the pump to function as an in vivo resistance factor.

Here it is shown by the analysis of Abcc10−/− fibroblasts that the pump contributes to inherent cellular resistance towards each of the classes of anticancer agents that we identified in the context of transfected HEK293 cells, including the taxanes paclitaxel and docetaxel (12, 13). Importantly, the results of experiments on Abcc10−/− MEFs, in combination with the finding that Abcc10−/− mice are hypersensitive to paclitaxel, provide the first evidence that the pump can function as an in vivo resistance factor. In addition, analysis of the tissue-specific pattern of toxicity provides insights into how genetic deficiency of Abcc10 contributes to paclitaxel hypersensitivity. Neutropenia in conjunction with marked bone marrow hypoplasia indicate that the pump affords protection against paclitaxel-induced bone marrow toxicity and suggest that reduced immunity is a significant component of morbidity in the Abcc10–null mice challenged with this agent. This is a noteworthy finding because bone marrow toxicity is the principal acute side effect of paclitaxel in humans. Additional insights into the contribution of Abcc10 to in vivo resistance will require studies on the impact of the pump on pharmacokinetics and associated determinations of the polarity and expression of Abcc10 in tissues involved in drug disposition.

While ABCC10 has been reported to have a wide pattern of transcript expression in human (13) and mouse tissues (present study), relatively little information is available on its expression in tumors and its susceptibility to induction under drug pressure. In a small survey involving 8 samples, ABCC10 transcript was detected in breast, lung, colon, prostate, ovary and pancreatic cancers (20). Another study described expression of ABCC10 transcript in 12 of 17 non-small cell lung cancer cell lines and reported that expression correlates with resistance of the cell lines to paclitaxel (21). With respect to inducibility, upregulation of ABCC10 transcript has been reported for a few cell lines made resistant to classes of microtubule active agents that we previously determined to be part of the pump’s drug resistance profile. Upregulation of ABCC10 transcript was reported for a small cell lung cancer cell line made resistant to paclitaxel, a non-small cell lung cancer cell line with acquired resistant to vinorelbine and salivary gland adenocarcinoma cell line made resistant to vincristine (2123). More information is needed on expression of ABCC10 in tumor samples, and in particular on tumors treated with taxanes and vinca alkaloids.

Although efflux pump inhibitors have yet to be established as a clinical strategy for sensitizing tumors to chemotherapeutic agents, the determination here that genetic deficiency of Abcc10 is not associated with obvious health problems indicates that the normal physiological functions of the murine pump are not essential, and suggests that ABCC10 inhibitors could potentially be used in humans without side effects attributable to interference with the pump’s normal functions. Several inhibitors of ABCC10 have been identified, including cepharanthine, lapatinib and nilotinib (2426). These compounds could serve as starting points for the development of potent and selective ABCC10 inhibitors.

Supplementary Material


This work was supported by National Institutes of Health grants K01CA120091 to EH-B, CA073728 to GDK,1R15CA143701 to ZSC and CA06927 to Fox Chase Cancer Center. We thank Dr. Samuel Litwin for statistical analyses and Dr. Erica Golemis for critical comments on the manuscript. We also thank the Laboratory Animal Facility, particularly Jackie Valvardi and Simon Tarpininan, for assistance with animal maintenance.


1. Zelnak AB. Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. Methods Mol Med. 2007;137:209–234. [PubMed]
2. Kruh GD. Ins and outs of taxanes. Cancer Biol Ther. 2005;4:1030–1032. [PubMed]
3. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–7295. [PubMed]
4. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer. 2005;92:E25–E30. [PubMed]
5. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11:298–305. [PubMed]
6. Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung. 2003;181:267–273. [PubMed]
7. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration. 2003;70:32–35. [PubMed]
8. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004;93:98–106. [PubMed]
9. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, Kruh GD. Analysis of the structure and expression pattern of MRP7(ABCC10), a new member of the MRP subfamily. Cancer Lett. 2001;162:181–191. [PubMed]
10. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007;453:675–684. [PubMed]
11. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003;22:7537–7552. [PubMed]
12. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. 2004;64:4927–4930. [PubMed]
13. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009;69:178–184. [PMC free article] [PubMed]
14. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10) Mol Pharmacol. 2003;63:351–358. [PubMed]
15. Belinsky MG, Dawson PA, Shchaveleva I, et al. Analysis of the In Vivo Functions of Mrp3. Mol Pharmacol. 2005 [PubMed]
16. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. 2001;61:1469–1476. [PubMed]
17. Kuang YH, Shen T, Chen X, et al. Lapatinib and erlotinib are potent reversal agents for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2010;79:154–161. [PMC free article] [PubMed]
18. Chen ZS, Aoki S, Komatsu M, et al. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer. 2001;93:107–113. [PubMed]
19. Izumchenko E, Singh MK, Plotnikova OV, et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009;69:7198–7206. [PMC free article] [PubMed]
20. Takayanagi S, Kataoka T, Ohara O, Oishi M, Kuo MT, Ishikawa T. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J Exp Ther Oncol. 2004;4:239–246. [PubMed]
21. Oguri T, Ozasa H, Uemura T, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther. 2008;7:1150–1155. [PubMed]
22. Bessho Y, Oguri T, Ozasa H, et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep. 2009;21:263–268. [PubMed]
23. Naramoto H, Uematsu T, Uchihashi T, et al. Multidrug resistance -associated protein 7 expression is involved in cross resistance to docetaxel in salivary gland adenocarcinoma cell lines. International Journal of Oncology. 2007;30:393–401. [PubMed]
24. Zhou Y, Hopper-Borge E, Shen T, et al. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2009;77:993–1001. [PubMed]
25. Kuang YH, Shen T, Chen X, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2009 [PMC free article] [PubMed]
26. Shen T, Kuang YH, Ashby CR, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7(ABCC10) PLoS One. 2009;4:e7520. [PMC free article] [PubMed]